FDA 483 - ProRx LLC - September 19, 2025
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
ProRx LLC received a Form 483 with seven observations, primarily concerning significant deficiencies in aseptic processing, environmental monitoring, and quality control for sterile drug products. The inspection revealed failures to thoroughly investigate microbial contamination events, inadequate aseptic techniques, and insufficient validation of sterilization processes. Additionally, the firm's quality unit lacked proper oversight, and drug product labels were found to be non-compliant with federal regulations.
ID · d14c5bac-5a22-4719-965c-991694c12636